Most neuromuscular disorders are rare (orphan) diseases, meaning that fewer than 1 in 2000 people are affected. They all cause a weakening of muscles, which could lead to tremendous disability. Because of this, international collaboration is extremely important to accelerate our knowledge and discovery of new medicines in the field of neuromuscular diseases.
ENMC reviews workshop applications bi-annually
Submission deadlines: 1 March and 1 September 2021
Guidelines how to provide care to neuromuscular patients who are affected by Covid-19:
Update to WMS advice Covid-19 and Deconfinement (May 12 2020)
Link to the WMS advice on Vaccines (Dec 23, 2020)
Go to the translations
This is ENMC at a glance:
https://www.enmc.org/wp-content/uploads/2019/04/CWTS_report.png
244
162
Annelies Zittersteijn
https://www.enmc.org/wp-content/uploads/2018/07/logo-224x300.png
Annelies Zittersteijn2019-04-01 12:30:072019-04-01 12:43:59ENMC bibliometric report published
https://www.enmc.org/wp-content/uploads/2018/09/973.gif
160
120
Alexandra Breukel
https://www.enmc.org/wp-content/uploads/2018/07/logo-224x300.png
Alexandra Breukel2019-03-12 09:16:152019-03-15 16:45:27Publication on the impact of 25 years ENMC workshops
https://www.enmc.org/wp-content/uploads/2019/02/JND6-1_PR1_social-media-visual.jpg
581
820
Alexandra Breukel
https://www.enmc.org/wp-content/uploads/2018/07/logo-224x300.png
Alexandra Breukel2019-02-07 18:00:062019-07-08 16:10:12Press release - ENMC publication about the role of patients in NMD research“The mission of ENMC is to encourage and facilitate communication and collaboration in the field of neuromuscular research with the aim of improving diagnosis and prognosis, finding effective treatments and optimising standards of care to improve the quality of life of people affected by neuromuscular disorders.”
